  |
 | Up a level |
Turner, N.C. and Slamon, D.J. and Ro, J. and Bondarenko, I. and Im, S.-A. and Masuda, N. and Colleoni, M. and DeMichele, A. and Loi, S. and Verma, S. and Iwata, H. and Harbeck, N. and Loibl, S. and André, F. and Puyana Theall, K. and Huang, X. and Giorgetti, C. and Huang Bartlett, C. and Cristofanilli, M. (2018) Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. The New England Journal of Medicine, 379. pp. 1926-1936. ISSN 0028-4793
Cristofanilli, M. and Slamon, D.J. and Ro, J. and Bondarenko, I. and Im, S-A. and Masuda, N. and Colleoni, M. and DeMichele, A. and Loi, S. and Verma, S. and Iwata, H. and Harbeck, N. and Loibl, S. and Andre´, F. and Puyana Theall, K. and Huang, X. and Giorgetti, C. and Huang Bartlett, C. and Turner, N.C. (2018) Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER22) advanced breast cancer (ABC): Analyses from PALOMA-3. Annals of Oncology, Vol.29 (Sapp.8). viii708-viii708. ISSN 0923-7534 (Print), 1569-8041 (Electronic)
